CA2949793C — Heteroaryl compounds for kinase inhibition
Assigned to Takeda Pharmaceutical Co Ltd · Expires 2024-02-27 · 2y expired
What this patent protects
Compounds of Formula Bf, pharmaceutical compositions comprising same, uses thereof for modulating kinase activity, including mutant EGFR and mutant HER2 kinase activity, and uses thereof for treating diseases and conditions associated with kinase activity, including mutant EGFR …
USPTO Abstract
Compounds of Formula Bf, pharmaceutical compositions comprising same, uses thereof for modulating kinase activity, including mutant EGFR and mutant HER2 kinase activity, and uses thereof for treating diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein: (formula Bf)
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.